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BACKGROUND: N-acetyltransferase-2 (NAT2) enzyme, encoded by NAT2 gene, plays a key role in metabolism of anti-tuberculosis (TB) drug 
isoniazid. Polymorphisms in NAT2 gene may result in 
different responses to TB therapy. Since TB prevalence in 
the  eastern  part  of  Indonesia  is  high,  the  aim  of this study 
is to explore the distribution of NAT2 gene polymorphisms 
among population from Kupang, Nusa Tenggara Timur.  
METHODS: A total of 234 respondents were included 
from Kupang in 2012. Polymorphisms of NAT2 gene 
were examined  using  mass  screening  platform  and  the 
genotypes distribution were presented in percentage. To 
confirm NAT2 gene polymorphisms, polymerase chain 
reaction (PCR)-sequencing was performed in a subset of 
population.
RESULTS:  The polymorphisms of NAT2 gene showed 
that the distribution of rs1801279 for GG genotype was 
100%;  whereas the genotype distribution of  rs1799930 for 
GG, GA and AA was 57%, 35.1% and 7.9%, respectively. 
In a subset of individuals (n13), acetylator status was well 
determined by PCR-sequencing, resulting in individual 
with wild type fast acetylator (NAT2*4; n4), intermediate 
(NAT2*4/*5 or NAT2*4/*6 or NAT2*4/*7; n7) and poor 
acetylators (NAT2*6/*6 or NAT2*7/*7; n2).
CONCLUSION: The amino acid change in rs1799930 
result in intermediate and poor acetylator status in Kupang 
population. This may lead to suboptimal response of TB 
therapy. Assessing acetylator status before TB therapy is 
important and may serve as personalized INH therapy. 
KEywORDS: NAT2 gene, polymorphism, acetylator 
status, Kupang
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Abstract
Introduction
N-acetyltransferase-2 (NAT2) enzyme plays a key role in 
metabolism of a variety of drugs, including anti-tuberculosis 
(TB) drug isoniazid (INH).(1) This enzyme is encoded by 
polymorphic NAT2 gene which is located at chromosome 
8, identified as 8p22. There are at least 7 single nucleotide 
polymorphisms (SNPs) in NAT2 gene, i.e., nucleotide (nt) 
change of 191G>A at rs1801279, nt282C>T at rs1041983, 
nt341T>C at rs1801280, nt481C>T at rs1799929, nt590G>A 
at rs1799930, nt803A>G at rs1208, and nt857G>A at 
rs1799931, respectively. The distribution of these SNPs is 
listed in the International data base and has been reported 
differently in various ethnicities around the globe.(2) 
 Of note, the nucleotide change does not always result 
in a change of coded amino acid, for example at the position 
nt282C>T and nt481C>T; whereas in other positions amino 
acid do change, for example at the position nt590G>A 
there is a change from arginine (Arg) to glutamine (Gln) 
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or at the position nt857 there is a change from glycine 
(Gly) to glutamic acid (Glu). Combination of these SNPs 
determines haplotypes of NAT2 gene result in various host 
acetylator status, that influences the NAT2 enzyme activity. 
For example, two normal allele of NAT2*4 or homozygous 
wild-type, designated as NAT2*4/*4 genotypes has fast or 
rapid enzyme activity, and this individual is identified as 
rapid or fast acetylator; whereas poor or slow acetylator 
has two mutant alleles with possible combination of 
genotypes such as nt481C>T, nt590G>A or nt857G>A, 
designated as NAT2*5, NAT2*6 or NAT2*7, respectively. 
Intermediate acetylator has one normal allele NAT2*4 in 
combination with one mutant allele NAT2*5, NAT2*6 or 
NAT2*7.(3) Rapid acetylator may develop in a suboptimal 
dose of drugs. In the other side of the coin, slow acetylator 
individuals may develop in an overdose leading to 
drug-induced hepatotoxicity or adverse drugs response. 
Therefore, adjustment of INH dose in TB therapy might be 
needed and serve as a personalized medicine.(4) Likewise 
the distribution of NAT2 polymorphisms, the prevalence of 
acetylator status have been reported differently in various 
ethnicities.(5,6,7) 
 A study in Java island, located in the western part of 
Indonesia, has shown that slow acetylator is occurred in 
35% of the population.(8) This might have an impact in the 
management of TB therapy, especially since Indonesia ranks 
second in TB prevalence in the world.(9) The high frequency 
of slow acetylators in this western part of Indonesia raises 
some concerns for TB therapy complication resulting in 
INH-induced hepatitis. INH has been used as preventive 
therapy according to National TB Program in high burden 
TB countries, and this may increase the role of screening of 
the acetylator status in the population. Therefore, acetylator 
status detection is needed since this acetylator status is 
clinically relevant prior to INH therapy to adjust the dose of 
treatment. 
 There are several methods to determine the host 
acetylator status (l) i.e., polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP), PCR-
direct sequencing and many other recent new techniques 
using automatic genotyping SNP platform for robust mass 
screening.(10) The aim of this study was to explore the NAT2 
gene polymorphisms and to determine the acetylator status 
by using mass screening platform among population in 
Kupang, a region in the eastern part of Indonesia where TB 
prevalence is higher compared to the west.(11) Moreover, 
the ethnicity in Kupang is originally different compared to 
ethnicity in Java. Therefore, acetylator status study in the 
eastern part of Indonesia might give valuable information 
for TB control program in Indonesia. 
Methods
This study was part of a larger study identifying susceptibility 
genes related to TB infection in the city of Kupang, Nusa 
Tenggara Timur, Indonesia. The initial study recruited 
newly TB patients (n124) diagnosed from Prof. Dr. W. Z. 
Johannes Hospital in Kupang and their healthy controls 
(n124) from the same house where TB patients lived. In 
brief, TB patients were diagnosed according to the standard 
hospital procedure as directed in WHO guideline, including 
history taking of TB infection, physical examination, chest 
X-ray, positive sputum, and positive mycobacterial culture. 
Patients with HIV and Diabetes Mellitus (n14) were 
excluded previously in the susceptibility study to TB. 
 This study explored NAT2 gene polymorhpisms in 
the population, thus both patients and control (n234) who 
were originally ‘by saying’ from ethnicity in the Timor 
island, where Kupang is located, were included in this 
current NAT2 gene study. The last name of the respondents 
would confirm the ethnicity from Timor island. No further 
exclusion criteria in this study since all participants with the 
same ethnicity would represent the genetic background of 
population. After reading and explaining the information 
of the study, all participants signed informed consent. The 
ethical clearance was approved by the Ethical Committee 
from Faculty of Medicine Universitas Padjadjaran Bandung 
under No.136/UN6.C2.1.2/KEPK/PN/2012.
 Vein blood was drawn and collected in a 3mL EDTA 
tube and stored in cold condition (+4C) prior sending 
to Bandung located in Java island, in the Western part 
of Indonesia, where DNA was isolated according to the 
manufacturer’s protocol (QIAamp DNA Blood Mini Kit, 
Cat No.51104, Qiagen). 
Genotyping of Single Nucleotide Polymorphisms in 
NAT2 Gene  
In total, 7 polymorphisms in NAT2 gene, including 
191G>A at rs1801279, nt282C>T at rs1041983, nt341T>C 
at rs1801280, nt481C>T at rs1799929, nt590G>A at 
rs1799930, nt803A>G at rs1208, and nt857G>A at 
rs1799931, were examined (the GoldenGate® Genotyping 
Assay for VeraCode®/BeadXpress Illumina®). The machine 
used in this study can mass screen of 96 participants in each 
plate and detect up to 48 SNPs. In brief, DNA was activated 
to bind to paramagnetic samples, and hybridization was 
followed according to manufacturer’s protocol. Microbead 
code was  then identified and fluorescent signal was detected 
(BeadXpress® Reader). During scanning, a laser beam 
penetrates the digitally inscribed to generate a unique code 
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image. Data was generated and analyzed by data analysis 
software (Illumina’s GenomeStudio®). The distribution of 
each  allele  and  genotype  of  each  rs  number  were 
counted for the frequency and compared to published global 
frequency.(16,19)
NAT2 Gene Sequencing
To confirm the polymorphisms in NAT2 gene, NAT2 gene 
was sequenced. In brief, forward primer of 5’-GGG ATC 
ATG GAC ATT GAA GC-3’ and reverse primer of 5’-GGG 
TGA TAC ATA CAC AAG GGT TTA-3’ were self-designed. 
The total volume of 50µL PCR solution consisting of 25µL 
Master Mix solution (Kappa2G Fast, Kapabiosystems), 
19µL deionized water, 2µL forward primer, 2µL reverse 
primer, and 2 µL of the DNA. The PCR condition was initial 
denaturation at 94°C for 3 min, followed by 30 cycles of 
denaturation at 94°C for 30 sec, annealing at 55°C for 30 
sec, and extension at 72°C for 1 min with the final extension 
at 72°C for 5 min. PCR product of 870 bp was visualized 
on 1% agarose gel running for 20 min at 90V before further 
sequencing process (BigDye® Terminator v3.1 cycle 
sequencing, done by the 1st BASE, Kuala Lumpur). 
Acetylator Status Determination from 7 Polymorphisms 
in NAT2 Gene
The acetylator status determination was assessed using 7 
most important NAT2 SNP i.e., rs1801279 for 191G>A, 
rs1041983 for 282C>T, rs1801280 for 341T>C, rs1799929 
for 481C>T, rs1799930 for 590G>A, rs1208 for 803A>G, 
and rs1799931 for 857G>A. Individual is classified as 
fast, intermediate, or slow acetylator, depending on NAT2 
diplotypes, as published elsewhere.(12) The nucleotide 
change at rs1801280 341 T>C, rs1799930 590 G>A, and 
rs1799931 857 G>A, were designated as NAT2*5, NAT2*6, 
NAT2*7, respectively. Results
In total, 234 participants with ethnicity from Timor island 
area were included in this study, consisting of 107 male 
(45.7%) and 127 female (54.3%) with mean age of 36.7 
years old (SD 13.6 years old). In a mass screening of 7 
polymorphisms in NAT2 gene, only 2 of 7 positions were 
detected i.e., rs1801279 or nt191 for nucleotide change 
of G>A and rs1799930 or nt590 for nucleotide change 
of G>A. The genotype frequency of rs1801279 showed 
100% GG, thus it was monomorphic; whereas rs1799930 
showed genotype frequency of GG, GA and AA for 57%, 
35,1%,7.9%, respectively, as summarized in Table 1. 
 Frequencies of the genotypes in one plate of 96 
individual were also depicted for rs1801279 (Figure1) and 
for rs1799930 (Figure 2) as shown using GenomeStudio®. 
Furthermore, rs1801279 and rs1799930 genotype 
distribution in Kupang was compared to other population, 
showing similarity to population studied in East Asian 
countries (Figure 3) (16,19).
rs number Nucleotide GG (%) GA (%) AA (%)
rs1801279 nt191 G>A 100 0 0
rs1799930 nt590 G>A 57 35.1 7.9
Table 1. Distribution of SNPs NAT2 gene at rs1801279 and 











Figure 1. Distribution of SNP NAT2 gene rs 1801279 
in population from Kupang, as shown using Illumina’s 
GenomeStudio®. Every single dot represents individuals 
genotyped in one plate for 96 individuals. Pink area is designated 
as genotype AA, purple area as GA, blue area as GG (wild type), 
respectively. 
Figure 2. Distribution of SNP NAT2 gene rs 1799930 
in population from Kupang, as shown using Illumina’s 
GenomeStudio®. Every single dot represents individuals 
genotyped in one plate for 96 individuals. Pink area is designated 
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 In a subset of the population (n13), acetylator status 
was well determined using PCR-sequencing method, 
resulting in individuals with rapid acetylators (NAT2*4/*4; 
n=4), intermediate acetylators (n7, including NAT2*4/*5 
n=1; NAT2*4/*6 n=1; NAT2*4/*7 n=5) and poor acetylators 
(n2, including NAT2*6/*6 n=1; NAT2*7/*7 n=1) as detailed 
in Table 2. Furthermore, we have assessed the results of 
rs1801279  and  rs1799930  using  PCR-sequencing  and 












Figure 3. The distribution of rs180279 and rs1799930 in population from Kupang compared to other populations.
rs1801279 rs1041983 rs1801280 rs1799929 rs1799930 rs1208 rs1799931
Nucleotide 






(synonymous) R197Q K268R G286E
NAT2 
haplotype NAT2*5 NAT2*6 NAT2*7
NAT2*4 . . . . . . . Fast/Rapid
NAT2*4 . . . . . . . Fast/Rapid
NAT2*4 . . . . . . . Fast/Rapid
NAT2*4 . . . . . . . Fast/Rapid
NAT2*4/*5 . CT TC CT . . . Intermediate
NAT2*4/*6 . CT . . GA . . Intermediate 
NAT2*4/*7 . CT . . . . GA Intermediate
NAT2*4/*7 . CT . . . . GA Intermediate
NAT2*4/*7 . TT . . GA . GA Intermediate
NAT2*4/*7 . TT . . GA . GA Intermediate
NAT2*4/*7 . TT . . GA . GA Intermediate
NAT2*6/*6 . TT . . AA . . Poor
NAT2*7/*7 . TT . . . . AA Poor
Acetylator 
phenotype
Table 2. The polymorphisms in NAT2 gene and acetylator status determination in a subset of population from Kupang, East Nusa 
Tenggara, using PCR-sequencing method.
Discussion
TB is an infectious disease, caused by mycobacterium 
tuberculosis. INH has been used as one of the anti-
TB therapy according to WHO guideline (9) and also 
encouraged for preventive drug in children.(13) NAT2 
enzyme plays a key role in metabolism of INH. To control 
the TB prevalence in high burden area, host genetic factor, 
among others NAT2 gene polymorphisms may play an 
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important role in response to TB therapy. Our study 
describes the distribution of NAT2 gene polymorphisms in 
population in Kupang, Nusa Tenggara Timur, Indonesia, 
where TB prevalence in this area is high. Ideally, to have 
NAT2 prevalence in an particular area or community, 
randomized community samples should be used. However, 
since NAT2 gene is close related to pharmacogenomics in 
TB, we have used the respondents consisting of TB patients 
and their controls to represent the prevalence in Kupang, 
that limits our current study. Nevertheless, assessing the 
NAT2 gene polymorphisms and thus the acetylator status 
in an area where TB prevalence is high, may optimize the 
strategy of TB control.
 The NAT2 gene polymorphisms distribution has been 
reported differently in various ethnicities worldwide and 
this NAT2 gene diversity may have implications for NAT2 
evolutionary history.(14) Our result has shown that the 
monomorphic rs1801279 genotype distribution in Kupang 
was  similar to population studied in the neighbor land 
Thailand (15) and many other East Asian population.(16) 
Interestingly, the study from Africa showed a very different 
distribution compared to the Kupang population.(16) In 
the case of population from Kupang and Timor island, 
this may be not true since the genetic background of this 
population is presumed to be derived from the African 
origin. African genetic diversity in human and pathogen 
may have implications for human demographic history, 
modern human origins, and complex disease mapping.(17) 
Previous group in Kupang has showed that mycobacterium 
tuberculosis Family F (East African-Indian) and family D 
(Latin American and Mediterranean) were more prevalent 
to infect the population in Timor (33.3% and 20.0%, 
respectively), suggesting a host-pathogen relation.(18) As 
for rs1799930, genotype distribution from Kupang does not 
differ that much compared to global population.(19) 
 Ebeshi, et al., has shown that the most common 
SNPs in NAT2 gene that play a key role are the nucleotide 
change at rs1801279 or 191G>A, rs1801280 341 T>C, 
rs1799930 590 G>A, and rs1799931 857 G>A, as those 
mutations alone or in combination might have changes in 
activity, stability or specificity of NAT2 enzyme.(7) Since 
only 2 polymorphisms data were available in our study, 
the complete acetylator status of these population could 
not be determined. The monomorphic rs1801279 genotype 
in this study does not account for the acetylator status 
determination. The rs1799930 polymorphisms in our study 
showed that there is a nucleotide change from guanine 
to adenine. This amino acid change from Arg to Gln at 
R197Q, designated as NAT2*6, indicating that the slow 
acetylators (AA genotype)  and  intermediate  acetylators 
(GA genotype) in this population is accounted for at least 
7.9% and 35.1%, respectively. If data of other SNP i.e., 
rs1801280 341 T>C (NAT2*5) and rs1799931857 G>A 
(NAT2*7) available, the percentage of slow acetylator could 
be counted and compared with the study in Jakarta, which 
is around 40%.(8) The slow acetylator may develop drug 
induced liver intoxicity, therefore, this high percentage is 
alarming, since Indonesia has high TB prevalence, being the 
second worldwide.(9)   
 Furthermore, geographic and ethnic variation in the 
frequency of NAT2 genotypes associated with rapid or 
intermediate  acetylator  (5,6),  as  well  as  slow acetylator 
(20) have been reported. Pharmacology study in Japan 
clearly showed, that the metabolism of INH by NAT2 
enzyme  is  impaired  in  subjects  with  NAT2  gene 
mutations (21), however, study in Chinese population could 
not find any significant  association  between  NAT2  gene 
genotype and the  hepatotoxicity.(22)  Although  it  is  still 
questionable, whether NAT2 genotype is necessary for 
personalize INH doses (23), study in Indonesia confirms 
a significant association between slow acetylators and 
susceptibility to liver  injury  induced  by  INH.(24)  Further 
pharmacogenetic study in Indonesia is needed to explore the 
association between  NAT2  gene  polymorphisms  and  INH 
metabolism.
 The  limitation  of  this  study is  that  the  mass 
screening of NAT2 gene polymorphism  cannot be  optimally 
conducted, however, individual screening by using PCR-
sequencing method can still be well performed to determine 
acetylator status. Since the acetylator status is clinically 
relevant prior to INH therapy to adjust the dose of treatment, 
especially in the area where TB prevalence is high, we 
therefore suggest that individual NAT2 PCR-sequencing 
method is suitable to guide for a personalized therapy for 
successful TB treatment. 
Conclusion
The rs1801279 NAT2 gene in population from Kupang 
is monomorphic, whereas based on the distribution of 
rs1799930 or nt590 polymorphism, it is predicted that 
the intermediate (GA genotype) and poor acetylator (AA 
genotype) in population from Kupang is as low as 35.1% 
and 7.9%, respectively.  It is worthy noted that acetylator 
status determination is needed, especially in the high TB 
burden area. PCR-sequencing of NAT2 gene is of great help 
in determining acetylator status.
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